Infectious Disease Treatment Market in China 2016-2020

About the Infectious Disease Treatment Market in China

Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic.

The analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Gilead Sciences
- GSK
- Johnson & Johnson
- Merck
- Pfizer

Other prominent vendors
- Achaogen
- Actelion
- Adenovir Pharma
- AstraZeneca
- Bayer
- Biocryst
- Celsius therapeutics
- Cempra
- Eleven Biotherapeutics
- Exoxemis
- Ferrer International
- Griffin Discoveries
- Hexima
- InSite Vision
- Insmed Incorporated
- KaloBios Pharmaceuticals
- Lytix Biopharma
- Meiji Seika Pharma
- Melinta Therapeutics
- Moberg Pharma
- NanoViricides
- Nektar
- NicOx
- NovaBay
- NovaBiotics
- Ocular Therapeutix
- Panoptes Pharma
- Paratek Pharmaceuticals
- Polichem
- PTC Therapeutics
- RedHill
- Shire
- Starpharma Holdings
- Sun Pharma
- Symbiomix
- Tetraphase Pharmaceuticals
- The Medicines Company
- Theravance Biopharma
- Topica Pharmaceuticals
- Vertex Pharmaceuticals
- Viamet Pharmaceuticals

Market drivers
- Use of combination therapies
- For a full, detailed list, view the full report

Market challenges
- Development of drug resistant strains
- For a full, detailed list, view the full report

Market trends
- Emergence of interferon (IFN)-free therapies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
- Local vendors
- Global vendors

PART 07: Pipeline analysis
- AC-170
- DEXTENZA
- Zerbaxa
- Surotomycin
- MK-3415A
- Amikacin Inhale
- CARBAVANCE
- Eravacycline
- Plazomicin
- Delafloxacin
- Solithromycin
- VivaGel
- Arikayce
- Cadazolid
- Ozenoxacin
- TDT 067
- MOB-015
- 1334H
- Auriclosene
- EBI-005
- FST-100
- VT-1161
- Luliconazole solution, 10%
- ME1111
- NP213
- HXP124
- SPL7013
- OPX-1
- AzaSite Xtra (ISV-405)
- GD134

PART 08: Market landscape
- Pharmaceutical market in China
  - Market overview
  - Market size and forecast
  - Five forces analysis

PART 09: Market segmentation by application

PART 10: Antibacterial drugs market in China
- MOA
- Market size and forecast

PART 11: Antiviral drugs market in China
- Market size and forecast
- Market segmentation by disease
- Hepatitis C drugs market in China
- Hepatitis B drugs market in China
- HIV drugs market in China

PART 12: Antifungal drugs market in China
- Market size and forecast

PART 13: Antiparasitic drugs market in China

PART 14: Market drivers
- Climatic changes
- Increased exposure to chemicals and pollutants
- Use of combination therapies
- Increased prevalence of infectious diseases
- Increase in awareness

PART 15: Impact of drivers

PART 16: Market challenges
- Counterfeit drugs
- Development of drug-resistant strains
- Patent expiries and generic penetration
- Decreased investments in research
- Increased use of generics and CAMs

PART 17: Impact of drivers and challenges

PART 18: Market trends
- Increase in collaborations and M&A
- Emergence of IFN-free therapies
- Increase in injection drug users

PART 19: Vendor landscape
- Competitive scenario
- F. Hoffmann-La Roche
- Gilead Sciences
- GSK
- Johnson & Johnson
- Merck
- Pfizer
- Other prominent vendors

PART 20: Appendix
- List of abbreviations

PART 21: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: China GDP 2010-2014 ($ trillions)
Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP)
Exhibit 04: Healthcare reforms in China
Exhibit 05: New drug approval (NDA) review process in China
Exhibit 06: New drug approval process in China
Exhibit 07: Drug registration classification and requirements in China
Exhibit 08: Infectious diseases treatment market in China: Pipeline portfolio
Exhibit 09: Pharmaceutical market in China 2015-2020 ($ billions)
Exhibit 10: China pharmaceutical market overview: SWOT analysis
Exhibit 11: Share of infectious diseases market in pharmaceutical market in China 2015
Exhibit 12: Infectious disease treatment market in China 2015-2020 ($ billions)
Exhibit 13: Venues for purchasing anti-infective drugs in China
Exhibit 14: Five forces analysis
Exhibit 15: Infectious disease treatment market in China segmentation by application
Exhibit 16: Infectious disease treatment market in China segmentation by application 2015
Exhibit 17: Infectious disease treatment market in China segmentation by application 2020
Exhibit 18: Infectious disease treatment market in China segmentation by application 2015-2020 ($ billions)
Exhibit 19: Infectious disease treatment market in China segmentation by application 2015-2020 (percentage)
Exhibit 20: Infectious disease treatment market in China 2015-2020
Exhibit 21: YoY growth rate of Infectious disease treatment market in China segments 2015-2020
Exhibit 22: MOA of antibacterial drugs
Exhibit 23: Antibacterial drugs market in China 2015-2020 ($ billions)
Exhibit 24: Segmentation of antibacterial drugs market by chemical class
Exhibit 25: Cephalosporin segmentation by generation of drugs
Exhibit 26: Antibacterial drugs market in China revenue segmentation by chemical class
Exhibit 27: Segmentation of antibacterial drugs market in China by drug origin
Exhibit 28: Antiviral drugs market in China 2015-2020 ($ billions)  
Exhibit 29: Segmentation of antiviral drugs market in China by disease 2015  
Exhibit 30: Segmentation of antiviral drugs market in China by disease 2020  
Exhibit 31: Hepatitis C drugs market in China ($ billions)  
Exhibit 32: Hepatitis B drugs market in China 2015-2020 ($ millions)  
Exhibit 33: Segmentation of hepatitis B and C market based on MOA  
Exhibit 34: HIV drugs market in China ($ millions)  
Exhibit 35: HIV drugs market segmentation by drug class 2015  
Exhibit 36: Antifungal drugs market in China 2015-2020 ($ millions)  
Exhibit 37: Antifungal drugs market in China segmentation by chemical class  
Exhibit 38: Antifungal drugs market segmentation by chemical class 2015  
Exhibit 39: Antiparasitic drugs market in China ($ millions)  
Exhibit 40: Impact of drivers  
Exhibit 41: Antibiotic-resistant strains according to the period of development of resistance  
Exhibit 42: Impact of drivers and challenges  
Exhibit 43: F. Hoffmann-La Roche: YoY revenue and growth rate of Pegasys (international) 2013-2015 ($ millions)  
Exhibit 44: F. Hoffmann-La Roche: YoY revenue and growth rate of Tamiflu (international) 2013-2015 ($ millions)  
Exhibit 45: F. Hoffmann-La Roche: Key takeaways  
Exhibit 46: Gilead Sciences: YoY revenue and growth rate of Truvada (international markets) 2013-2015 ($ millions)  
Exhibit 47: Gilead Sciences: YoY revenue and growth rate of Atripla (international markets) 2013-2015 ($ millions)  
Exhibit 48: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)  
Exhibit 49: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)  
Exhibit 50: Gilead Sciences: Key takeaways  
Exhibit 51: GlaxoSmithKline: Key takeaways  
Exhibit 52: Johnson & Johnson: YoY revenue and growth rate of Olysio (international markets) 2013-3015 ($ millions)  
Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Prezista (international markets) 2013-3015 ($ millions)  
Exhibit 54: Johnson & Johnson: YoY revenue and growth rate of Edurant (international markets) 2013-3015 ($ millions)  
Exhibit 55: Johnson & Johnson: Key takeaways  
Exhibit 56: Merck: YoY revenue and growth rate of Cancidas (international markets) 2013-2015 ($ millions)  
Exhibit 57: Merck: YoY revenue and growth rate of Pegintron (international markets) 2013-2015 ($ millions)  
Exhibit 58: Merck: YoY revenue and growth rate of Isentress (international markets) 2013-2015 ($ millions)  
Exhibit 59: Merck: YoY revenue and growth rate of Invanz (international markets) 2013-2015 ($ millions)  
Exhibit 60: Merck: YoY revenue and growth rate of Noxafil (international markets) 2013-2015 ($ millions)  
Exhibit 61: Merck: YoY revenue of Cubicin (international markets) 2013-2015 ($ millions)  
Exhibit 62: Merck: Key takeaways  
Exhibit 63: Pfizer: YoY revenue and growth rate of Diflucan (emerging markets) 2013-2015 ($ millions)  
Exhibit 64: Pfizer: YoY revenue and growth rate of Suplerazon (emerging markets) 2013-2015 ($ millions)  
Exhibit 65: Pfizer: YoY revenue and growth rate of Tygacil (Emerging markets) 2013-2015 ($ millions)  
Exhibit 66: Pfizer: YoY revenue and growth rate of Vfend (emerging markets) 2013-2015 ($ millions)  
Exhibit 67: Pfizer: YoY revenue and growth rate of Zithromax (emerging markets) 2013-2015 ($ millions)  
Exhibit 68: Pfizer: YoY revenue and growth rate of Zyvox (emerging markets) 2013-2015 ($ millions)  
Exhibit 69: Pfizer: YoY revenue and growth rate of Tygacil (emerging markets) 2013-2015 ($ millions)  
Exhibit 70: Pfizer: Key takeaways

Ordering:  
Order Online - http://www.researchandmarkets.com/reports/3752371/  
Order by Fax - using the form below  
Order by Post - print the order form below and send to  
Research and Markets,  
Guinness Centre,
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Infectious Disease Treatment Market in China 2016-2020
Web Address: http://www.researchandmarkets.com/reports/3752371/
Office Code: SCPLROE4

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World